Breaking Finance News

Needham recorded SAGE Therapeutics (NASDAQ:SAGE), scaling down its target to $86.00 earlier today

In a report issued 09/13/2017 Needham lowered the target price of SAGE Therapeutics (NASDAQ:SAGE) from $95.00 to $86.00 reporting a possible upside of 0.13%.

Having a price of $76.40, SAGE Therapeutics (NASDAQ:SAGE) traded 1.08% higher on the day. The last stock close price is up 3.15% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same time. The company has recorded a 50-day moving average of $83.06 and a 200-day moving average of $74.87. Trade Volume was down over the average, with 97,005 shares of SAGE changing hands under the typical 374,633

See Chart Below

SAGE Therapeutics (NASDAQ:SAGE)

With a market cap of $0, SAGE Therapeutics has 52 week low of $38.30 and a 52 week high of $90.80 .

Also covering SAGE Therapeutics's target, a total of 8 analysts have released a report on SAGE Therapeutics. The 12-month price target is $68.88 with 0 firms rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally zero analysts rating the company a sell.

General Company Details For SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *